NCT03717623 Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
| NCT ID | NCT03717623 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Melbourne Health |
| Condition | Posaconazole |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-08-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2019-08-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
Eligibility Criteria
Inclusion Criteria: * Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care. * Able to give informed consent. Exclusion Criteria: * Unable to give informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03717623 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Posaconazole. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03717623 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03717623 currently recruiting?
Yes, NCT03717623 is actively recruiting participants. Contact the research team at monica.slavin@mh.org.au for enrollment information.
Where is the NCT03717623 trial being conducted?
This trial is being conducted at Parkville, Australia.
Who is sponsoring the NCT03717623 clinical trial?
NCT03717623 is sponsored by Melbourne Health. The trial plans to enroll 100 participants.